WilmerHale Advises Alkermes in Acquisition of Rodin Therapeutics
On November 25, 2019, Alkermes plc announced the completion of its previously announced acquisition of Rodin Therapeutics, Inc., a privately held biopharmaceutical company focused on developing novel, small molecule therapeutics for synaptopathies. The WilmerHale team representing Alkermes was led by
Stuart Falber,
Joe Conahan and
Mark Nylen and included
Julie Hogan Rodgers,
Scott Kilgore,
Steve Barrett,
Bruce Manheim,
Barry Hurewitz,
Hartmut Schneider,
Paul Jakubowski,
Ben Unger,
Ben Kelsey,
Lauren Ige,
Meghan Fay and
Meghan Muncey.
